Board Member
Alx Oncology Holdings Inc (ALXO)Equibles does not estimate personal net worth.
Get an email with a short summary when Alx Oncology Holdings Inc publishes a filing, an earnings call transcript or a press release.
Get ALXO alertsJason Lettmann is recorded as Board Member at Alx Oncology Holdings Inc (ALXO) since January 1, 2020 and CEO at Alx Oncology Holdings Inc (ALXO). The newest filing on record that lists Jason Lettmann as CEO and Board Member at Alx Oncology Holdings Inc (ALXO) is dated April 20, 2026. Alx Oncology Holdings Inc reported in an 8-K filed September 6, 2023 that Jason Lettmann was appointed Chief Executive Officer, effective September 6, 2023. The proxy statement of Alx Oncology Holdings Inc reports total compensation of $2,470,844 for Jason Lettmann in fiscal 2025, including a base salary of $724,500. Disclosed compensation is on record for 4 fiscal years. Jason Lettmann has spoken on 4 earnings calls and 3 other investor events across 1 company, most recently for Alx Oncology Holdings Inc on September 14, 2026. Alx Oncology Holdings Inc is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Alx Oncology Holdings Inc includes Scott Garland (Chairman and Board Member), Harish Shantharam (CFO), Michael Listgarten (General Counsel) and 7 others.
“On September 6, 2023, ALX Oncology Holdings Inc. (the “Company”) appointed Jason Lettmann, age 46 and a current member of the Company’s Board of Directors (the “Board”), as the Company’s Chief Executive Officer.”
“There was a $2 billion acquisition that really didn't work. um so but why um do you think a wordpressant mechanistically is different and it's a better bet than on the same target yeah sure so i think you know cd47 like a lot of things in biotech there's been all sorts of ups and downs i think you could write a novel…”
“Harish is our CFO, but he's also our acting CMO in this panel. So if there's any tough clinical questions, Harish is the man for that. But, you know, it's an exciting time in the company.”
“And ALX really comes to a decade and really have been pleased over the last year to see, you know, the original thesis, the original vision of Vorpicep pan out in the clinic.”
“Really appreciate you all spending time with us this morning and are looking forward to sharing these updates with you. On slide two, and before we start our presentation as housekeeping, here are our forward-looking statements for your review.”
“Appreciate you all spending some time with us this morning. As usual, we will be making forward-looking statements during the call, so please refer to our FLS slide in our corporate deck.”
2020-01-01–present
Last confirmed April 20, 2026
Start not stated–present
Last confirmed April 20, 2026
Biotechnology · Healthcare
CEO, Board Member
2020-01-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Alx Oncology Holdings Inc (ALXO) | Chief Executive Officer | $724,500 | $2,470,844 |
| 2024 | Alx Oncology Holdings Inc (ALXO) | Chief Executive Officer | $700,000 | $6,640,830 |
| 2023 | Alx Oncology Holdings Inc (ALXO) | Chief Executive Officer | $217,330 | $4,857,183 |
| 2022 | Alx Oncology Holdings Inc (ALXO) | Chief Executive Officer | — | — |
